Unavailable
Unavailable
Save time and jump to the most important pieces.
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populationsNet proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the fir
15-12G - European Biotech Acquisition Corp. (0001841258) (Filer)
25-NSE/A - European Biotech Acquisition Corp. (0001841258) (Subject)
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)